Skip to content

Study · Animal study (in vivo) · rat · 2014

9 results

Kisspeptin-10 induces endothelial cellular senescence and impaired endothelial cell growth.

Usui S, Iso Y, Sasai M, Mizukami T, Mori H, Watanabe T, Shioda S, Suzuki H

Clinical science (London, England : 1979)1 Jul 2014Cited by 17 (Europe PMC)

PMID24405415 (opens in a new tab)DOI10.1042/cs20130505 (opens in a new tab)PepBankPUB-24405415
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with hindlimb ischaemia, recombinant KP-10 significantly impaired blood flow recovery compared with controls.

    In plain wordsIn rats with reduced leg blood flow, KP-10 slowed blood flow recovery compared with controls.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseBlood flow recovery after hindlimb ischaemia
    Study

    ratn: not reported in source

    Hindlimb ischaemia model
    Comparator
    Controls
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of recombinant KP-10 into the hindlimbs of rats with ischaemia significantly impaired blood flow recovery, as shown by laser Doppler, and capillary growth, as shown using histology, compared with the controls.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with hindlimb ischaemia, recombinant KP-10 significantly impaired capillary growth compared with controls.

    In plain wordsIn rats with reduced leg blood flow, KP-10 reduced new capillary growth compared with controls.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseCapillary growth after hindlimb ischaemia
    Study

    ratn: not reported in source

    Hindlimb ischaemia model
    Comparator
    Controls
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The administration of recombinant KP-10 into the hindlimbs of rats with ischaemia significantly impaired blood flow recovery, as shown by laser Doppler, and capillary growth, as shown using histology, compared with the controls.
  3. 03LabIn vitro (cells)Efficacy outcome

    In human umbilical vein endothelial cells, KP-10 inhibited tube formation in a significant, dose-dependent manner.

    In plain wordsIn cells, KP-10 reduced the ability of blood vessel cells to form tubes, more so at higher doses.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEndothelial cell tube formation
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 inhibited endothelial cell tube formation and proliferation in a significant and dose-dependent manner.
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.
  4. 04LabIn vitro (cells)Efficacy outcome

    In human umbilical vein endothelial cells, KP-10 inhibited proliferation in a significant, dose-dependent manner.

    In plain wordsIn cells, KP-10 slowed the growth of blood vessel cells, more so at higher doses.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEndothelial cell proliferation
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    KP-10 inhibited endothelial cell tube formation and proliferation in a significant and dose-dependent manner.
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.
  5. 05LabIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells, KP treatment produced a senescent phenotype by senescence-associated beta-galactosidase assay and cell morphology.

    In plain wordsIn cells, KP-10 pushed blood vessel cells into an aged, non-dividing state.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseSenescent phenotype of endothelial cells
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The HUVECs treated with KP exhibited the senescent phenotype, as determined using a senescence-associated β-galactosidase assay, cell morphology analysis
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.
  6. 06LabIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells, KP treatment decreased Sirt1 expression by Western blot.

    In plain wordsIn cells, KP-10 lowered the level of the Sirt1 protein in blood vessel cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSirt1 expression
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    decreased Sirt1 (sirtuin 1) expression and increased p53 expression shown by Western blot analysis
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.
  7. 07LabIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells, KP treatment increased p53 expression by Western blot.

    In plain wordsIn cells, KP-10 raised the level of the p53 protein in blood vessel cells.

    Peptide
    Kisspeptin-10
    Outcome
    Increasep53 expression
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    increased p53 expression shown by Western blot analysis
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.

Studies that did not test the peptide alone2

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 08LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells exposed to KP-10, the Rho kinase inhibitor Y-27632 increased proliferation.

    In plain wordsIn cells exposed to KP-10, a Rho kinase blocker increased the growth of blood vessel cells.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseHUVEC proliferation with Rho kinase inhibitor Y-27632 in KP-10-treated cells
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    a pharmacological Rho kinase inhibitor, Y-27632, was found to increase the proliferation of HUVECs
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  2. 09LabNot a test of Kisspeptin-10 aloneIn vitro (cells)Mechanism

    In human umbilical vein endothelial cells exposed to KP-10, the Rho kinase inhibitor Y-27632 reduced the number of senescent cells.

    In plain wordsIn cells exposed to KP-10, a Rho kinase blocker lowered the number of aged blood vessel cells.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSenescent cell number with Rho kinase inhibitor Y-27632 in KP-10-treated cells
    Study

    humann: not reported in source

    HUVECs
    Outcome group
    Aging markers · Aging and longevity

    Source sentences

    Summary
    to reduce the number of senescent phenotype cells affected by KP-10
    1 context sentence
    Summary · context
    HUVECs (human umbilical vein endothelial cells) express the KP receptor and were treated with KP-10 in culture studies.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.